BiotechTube
PharmaBiome

PharmaBiome

Basel, Switzerland· Est.
pharmabiome.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.5M

Overview

PharmaBiome is a pre-clinical stage biotech pioneering a function-based approach to microbiome therapeutics. Originating from ETH Zurich, its platform focuses on engineering consortia of bacteria based on their metabolic interactions to restore core functions lost in dysbiosis. The company has established key R&D collaborations with industry partners like Ferring and Roquette and is advancing its science towards targeted therapies for inflammatory and other microbiome-linked conditions.

Inflammatory Bowel DiseaseGastrointestinal Disorders

Technology Platform

Proprietary platform for function-based discovery, bottom-up engineering, and scalable co-cultivation of defined bacterial consortia to restore core metabolic networks in the gut microbiome.

Funding History

2
Total raised:$18.5M
Series A$15M
Seed$3.5M

Opportunities

The growing validation of the microbiome's role in chronic disease creates a large addressable market for targeted therapies.
PharmaBiome's function-based approach and scalable co-culture technology position it to overcome historical reproducibility challenges in the field.
Strategic partnerships with established players like Ferring provide capital, validation, and a potential path to market.

Risk Factors

The scientific hypothesis of treating via complex functional networks is unproven in clinical settings and faces significant technical and biological hurdles.
The regulatory pathway for live bacterial consortia is complex and evolving.
The company faces intense competition from numerous well-funded entities in the microbiome space.

Competitive Landscape

PharmaBiome competes in the crowded microbiome therapeutics sector against companies pursuing single-strain drugs, defined consortia (e.g., Vedanta Biosciences), and engineered bacteria. Its key differentiation is its foundational focus on metabolic function and network interactions over specific bacterial taxonomy, and its proprietary co-cultivation technology for manufacturing interactive consortia.

More companies in Microbiome Therapeutics →More companies in Switzerland →